Arcturus Therapeutics initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $20 price target The company has two mid-stage programs with evidence of clinical activity and over $1B of peak sales potential, the analyst tells investors in a research note. Roth says Arcturus shares trade near its cash position, implying 0% probability of success for both assets. This makes the company “potentially one of the most mispriced stocks in rare disease,” the firm contends.